J&J reports positive preclinical results for COVID-19 vaccine

By The Science Advisory Board staff writers

July 30, 2020 -- Johnson & Johnson reported that its lead COVID-19 vaccine candidate protected against SARS-CoV-2 in preclinical studies.

The results from the nonhuman primate study, published in Nature, demonstrated that the adenovirus serotype 26 (Ad26) vector-based vaccine elicited a strong immune response and successfully produced neutralizing antibodies against SARS-CoV-2. Moreover, the vaccine prevented subsequent infection after a single vaccine dose and there was no detectable virus in the lower respiratory tract after exposure to SARS-CoV-2.

A phase I/IIA clinical trial of the vaccine candidate, Ad26.COV2.S, is underway in the U.S. and Belgium and will enroll over 1,000 healthy adults to evaluate safety and immunogenicity. Planning is underway for a phase IIA study in the Netherlands, Spain, and Germany, and a phase I study in Japan.

The company intends to move into a phase III trial in September. This study will evaluate a single vaccine dose versus a placebo. Simultaneously, a phase III trial of a two-dose regimen will also be conducted.

Johnson & Johnson continues to increase manufacturing capacity and is in discussion with global partners to support worldwide access. If the vaccine is approved, the company aims to supply more than 1 billion doses globally by the end of 2021.

J&J to start clinical trial for COVID-19 vaccine in July
Johnson & Johnson is accelerating its investigational SARS-CoV-2 vaccine candidate, Ad26.COV2-S, recombinant, with the initiation of a phase I/IIA...
J&J announces manufacturing collaboration for COVID-19 vaccine
Johnson & Johnson, a Janssen Pharmaceuticals company, announced on April 24 a collaboration with Emergent BioSolutions to support the manufacturing...
J&J seeks to release COVID-19 vaccine by 2021
Johnson & Johnson has selected a lead COVID-19 vaccine candidate from a number of options it has been working on since January. The company hopes...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
BioProcess International
September 21-24
Eastern Standard Time Zone (EST), Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter